SecBot SecBot
8-K ·Filed May 14, 2026

RGNX

REGENXBIO Inc.
MIXED
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-222768
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The RGX-202 Phase III data is a transformative catalyst that could drive significant upside if the FDA accepts a BLA for accelerated approval. However, the cash runway is tight (into early 2027) and the company will likely need to raise capital before a potential approval. Monitor the Q4 2026 sura-vec wet AMD data readout and the $100M AbbVie milestone payment expected in Q2 2026, which would extend the runway.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.25
T+0 close · May 14, 2026 · via day close
Latest settled
+66.85%
T+60 · $10.42
Vs SPY
+63.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $6.25entry
  2. T+1 · 6mo ago −8.41%α −7.18% · $5.72
  3. T+5 · 6mo ago +8.09%α +8.80% · $6.75
  4. T+20 · 5mo ago +6.65%α +7.50% · $6.66
  5. T+60 · 3mo ago +66.85%α +63.26% · $10.42

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/share) vs. net income of $6.1M a year ago, as revenue collapsed 93% to $6.4M due to the absence of a prior-year $70M Nippon Shinyaku milestone and ZOLGENSMA royalty expiration. The cash burn is severe ($150.5M remaining, funding into early 2027). However, the filing is dominated by positive topline Phase III data for RGX-202 in Duchenne: the primary endpoint was met with high statistical significance (93% of patients achieved >10% microdystrophin expression, p<0.0001), and a statistically significant correlation between expression and functional improvement supports a potential accelerated approval pathway in 2027. The clinical hold on RGX-121 was also lifted. The combination of transformative pipeline catalysts and deteriorating financials creates a mixed picture.

Key Financial Metrics

EPS
−$1.72
est −$1.36 · -26.5%
Revenue
$6.4M
est $25.2M · -74.6% · -92.8% YoY
Rating
in line

Key Facts

  • Q1 2026 revenue $6.4M vs $89.0M YoY, down 93% due to absence of $70M Nippon Shinyaku milestone and ZOLGENSMA royalty expiration
  • Net loss $90.1M ($1.72/share) vs net income $6.1M ($0.12/share) in Q1 2025
  • Cash, cash equivalents and marketable securities $150.5M as of March 31, 2026, down from $240.9M at Dec 31, 2025
  • Cash runway into early 2027 based on current operational plans
  • Phase III AFFINITY DUCHENNE trial of RGX-202 met primary endpoint: 93% of patients achieved >10% microdystrophin expression (p<0.0001)
  • Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9)
  • Company plans to pursue accelerated approval for RGX-202 with potential commercial launch in 2027
  • FDA lifted partial clinical hold on RGX-121 for Hunter syndrome
  • AbbVie-partnered sura-vec (ABBV-RGX-314) on track: first patient dosed in DR Phase IIb/III expected Q2 2026; subretinal wet AMD pivotal data expected Q4 2026
  • Company will receive $100M milestone from AbbVie upon first patient dosed in NAAVIGATE study

Financial Impact

Revenue declined 93% YoY to $6.4M; net loss widened to $90.1M from net income of $6.1M; cash burn of $90.4M in Q1 2026

revenuenet incomecash positionR&D expenses

Risk Factors

  • Cash runway only into early 2027; likely need for dilutive financing before potential RGX-202 approval
  • RGX-202 accelerated approval path requires FDA acceptance of surrogate endpoint; regulatory risk remains
  • Revenue base collapsed 93% YoY with ZOLGENSMA royalty expiration and no recurring product revenue
  • RGX-121 CRL appeal ongoing; path forward uncertain despite clinical hold lift
  • Competitive landscape in Duchenne gene therapy (Sarepta, Pfizer, Solid Biosciences)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-222768
Document: 0001193125-26-222768-index.html0001193125-26-222768
Document: 0001193125-26-222768.txt0001193125-26-222768
8-K Data (Synthetic)0001193125-26-222768

Track record

15 reports on RGNX

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
  2. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
  3. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
  4. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
  5. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
  6. Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
  7. Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
  9. Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
  10. Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026